Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 11,161 matching trials from the live ClinicalTrials.gov search.
Conditions
Amyloidosis
Interventions
Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
16
States / cities
Duarte, California • New Haven, Connecticut • Tampa, Florida + 12 more
Conditions
Carcinoma, Non-small Cell
Interventions
Dacomitinib (PF-00299804)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
31
States / cities
Orange, California • Pleasant Hill, California • Salinas, California + 15 more
Active, not recruiting No phase listed Observational

NCI COVID-19 in Cancer Patients, NCCAPS Study

NCT04387656
Conditions
COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Data Collection, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
1,877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
928
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 589 more
Conditions
Melanoma
Interventions
Ipilimumab (BMS-734016), Vemurafenib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York
Terminated Phase 2 Interventional Results available

Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

NCT04926831
Conditions
Non-small Cell Lung Cancer
Interventions
capmatinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
La Jolla, California • Sacramento, California • Fairfax, Virginia
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Copper Intrauterine Device (IUD) Insertion at Cesarean Delivery

NCT01439802
Conditions
Intrauterine Device Expulsion
Interventions
Copper IUD placement at time Cesarean Delivery (Copper T 380A)
Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
The Bronx, New York
Conditions
HIV Infections
Interventions
GSK3640254, Darunavir/Ritonavir (DRV/RTV), Etravirine (ETR)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Conditions
Advanced Solid Tumor
Interventions
Nemvaleukin alfa, Pembrolizumab
Biological
Lead sponsor
Mural Oncology, Inc
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Grand Rapids, Michigan • Houston, Texas • West Valley City, Utah + 1 more
Conditions
Lymphoma, Non-Hodgkin
Interventions
DZD8586, Placebo
Drug
Lead sponsor
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Secaucus, New Jersey
Conditions
Acute Lymphoblastic Leukemia
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Breast Cancer
Interventions
Zelenectide pevedotin (BT8009)
Drug
Lead sponsor
BicycleTx Limited
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Baltimore, Maryland • Boston, Massachusetts • St Louis, Missouri + 5 more
Conditions
Cardiovascular Disease, Hypertension
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years to 100 Years
Enrollment
1,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Framingham, Massachusetts
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944

NCT01934205
Conditions
Infections, Bacterial
Interventions
GSK2140944 (Single dose), GSK2140944 (Multiple dose)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Colorectal Cancer, Liver Neoplasms
Interventions
NV1020
Drug
Lead sponsor
MediGene
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
San Diego, California • Boston, Massachusetts • Pittsburgh, Pennsylvania + 2 more
Conditions
Prostate Cancer
Interventions
Genomic Prostate Score assay and Multi-parametric magnetic resonance imaging study of the prostate
Other
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 76 Years · Male only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Chicago, Illinois
Conditions
Migraine
Interventions
Erenumab, Placebo, PACAP-38 Challenge Agent
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Anaheim, California
Conditions
Prostatic Neoplasms, Adenocarcinoma
Interventions
JNJ-69086420, JNJ-78278343, Stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
11
States / cities
Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 8 more
Active, not recruiting No phase listed Observational

PRE-DETERMINE Cohort Study

NCT01114269
Conditions
Coronary Artery Disease, Left Ventricular Dysfunction, Sudden Cardiac Death
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
5,764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2026
U.S. locations
86
States / cities
Anchorage, Alaska • Glendale, Arizona • Phoenix, Arizona + 76 more
Conditions
Myeloproliferative Neoplasms
Interventions
INCA033989, Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
13
States / cities
Duarte, California • Palo Alto, California • Miami, Florida + 9 more
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of BLKR201 in Healthy Adult Participants

NCT07501039
Conditions
Healthy
Interventions
BLKR201, Placebo
Drug
Lead sponsor
Formation Bio, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
Larotrectinib (Vitrakvi, BAY2757556)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
8
States / cities
Aurora, Colorado • Boston, Massachusetts • Cleveland, Ohio + 5 more
Conditions
Cystoid Macular Edema, Fuchs Dystrophy
Interventions
Optical Coherence Tomography
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Completed No phase listed Observational Accepts healthy volunteers

Contraceptive Hormones, Immunity, and Microbiome Evaluation

NCT03660046
Conditions
Hormonal Contraception
Interventions
Depot medroxyprogesterone acetate (DMPA), Etonogestrel implant (Eng-Implant), Levonorgestrel IUD (Lng-IUD)
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 45 Years · Female only
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
3
States / cities
Atlanta, Georgia
Conditions
Amaurosis of Leber, Retinal Diseases
Interventions
rAAV2-CBSB-hRPE65
Genetic
Lead sponsor
University of Pennsylvania
Other
Eligibility
8 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
2
States / cities
Gainesville, Florida • Philadelphia, Pennsylvania